Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Joseph Klein III sold 3,000 shares of the business’s stock in a transaction on Friday, December 29th. The stock was sold at an average price of $50.56, for a total transaction of $151,680.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Joseph Klein III also recently made the following trade(s):

  • On Saturday, December 29th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $50.56, for a total transaction of $151,680.00.
  • On Friday, December 15th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $51.69, for a total transaction of $155,070.00.
  • On Thursday, November 30th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $53.55, for a total transaction of $160,650.00.
  • On Wednesday, November 15th, Joseph Klein III sold 2,250 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $53.56, for a total transaction of $120,510.00.
  • On Monday, November 13th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $55.39, for a total transaction of $166,170.00.

Shares of Ionis Pharmaceuticals Inc (NASDAQ IONS) opened at $50.02 on Thursday. Ionis Pharmaceuticals Inc has a 1-year low of $37.26 and a 1-year high of $65.51. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. The company has a market cap of $6,146.18, a PE ratio of 333.49 and a beta of 2.86.

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Ionis Pharmaceuticals by 4.4% in the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after buying an additional 417,364 shares during the last quarter. BlackRock Inc. increased its stake in shares of Ionis Pharmaceuticals by 4.0% during the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after acquiring an additional 264,179 shares during the period. American Century Companies Inc. increased its stake in shares of Ionis Pharmaceuticals by 33.0% during the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after acquiring an additional 284,266 shares during the period. First Trust Advisors LP increased its stake in shares of Ionis Pharmaceuticals by 40.2% during the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after acquiring an additional 281,733 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Ionis Pharmaceuticals by 7.8% during the second quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock worth $31,631,000 after acquiring an additional 44,750 shares during the period. 91.40% of the stock is owned by institutional investors and hedge funds.

IONS has been the subject of a number of analyst reports. BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. BMO Capital Markets reiterated an “outperform” rating and set a $69.00 target price on shares of Ionis Pharmaceuticals in a research note on Monday, October 2nd. Barclays lowered their target price on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating for the company in a research note on Thursday, September 21st. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $50.31.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/01/04/joseph-klein-iii-sells-3000-shares-of-ionis-pharmaceuticals-inc-ions-stock.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related stocks with our FREE daily email newsletter.